TransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• TransMedics Group, Inc. has received an average rating of "Moderate Buy" from analysts, with a target price of $123.00.
• Insider trading activity includes Director David Weill selling 732 shares and Edward M. Basile selling 6,000 shares, resulting in a significant decrease in their ownership positions.
• TransMedics reported a strong performance in its latest earnings, with earnings per share of $0.92 and revenue growth of 37.7% compared to the previous year.

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the nine analysts that are currently covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $123.00.

Several analysts recently commented on the stock. Piper Sandler reissued an "overweight" rating and set a $145.00 price objective (up from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a research note on Tuesday, June 17th. Oppenheimer upped their target price on shares of TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a research note on Tuesday, June 17th. Wall Street Zen upgraded shares of TransMedics Group from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Finally, Morgan Stanley upped their target price on shares of TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a research note on Friday, August 1st.

Insider Transactions at TransMedics Group

In other news, insider Anil P. Ranganath sold 686 shares of the stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $139.80, for a total value of $95,902.80. Following the transaction, the insider owned 13,955 shares in the company, valued at $1,950,909. This represents a 4.69% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Edward M. Basile sold 5,000 shares of the stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $126.45, for a total transaction of $632,250.00. Following the completion of the transaction, the director owned 2,866 shares in the company, valued at $362,405.70. This trade represents a 63.56% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,418 shares of company stock worth $818,833 in the last quarter. Company insiders own 7.00% of the company's stock.

Hedge Funds Weigh In On TransMedics Group

Institutional investors have recently made changes to their positions in the business. NBC Securities Inc. bought a new stake in TransMedics Group during the 1st quarter worth approximately $25,000. Opal Wealth Advisors LLC bought a new stake in TransMedics Group during the 2nd quarter worth approximately $26,000. Smartleaf Asset Management LLC raised its stake in TransMedics Group by 44.3% during the 1st quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock worth $30,000 after acquiring an additional 135 shares during the period. Quarry LP raised its stake in TransMedics Group by 88.5% during the 1st quarter. Quarry LP now owns 592 shares of the company's stock worth $40,000 after acquiring an additional 278 shares during the period. Finally, Sound Income Strategies LLC bought a new stake in TransMedics Group during the 2nd quarter worth approximately $48,000. Institutional investors own 99.67% of the company's stock.

TransMedics Group Stock Down 1.3%

TMDX stock traded down $1.55 during trading on Wednesday, hitting $114.50. 731,219 shares of the stock traded hands, compared to its average volume of 1,403,726. TransMedics Group has a 1 year low of $55.00 and a 1 year high of $177.37. The firm's 50 day moving average is $123.84 and its two-hundred day moving average is $97.17. The stock has a market cap of $3.90 billion, a price-to-earnings ratio of 59.33 and a beta of 2.09. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.86 and a quick ratio of 9.17.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The company had revenue of $157.37 million for the quarter, compared to the consensus estimate of $146.64 million. During the same period in the prior year, the firm posted $0.35 EPS. TransMedics Group's revenue for the quarter was up 37.7% on a year-over-year basis. On average, sell-side analysts anticipate that TransMedics Group will post 1 EPS for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.